2018年2月28日星期三

A7RC peptide modified paclitaxel liposomes dually target breast cancer

A7RC peptide modified paclitaxel liposomes dually target breast cancer

J Cao, R Wang, N Gao, M Li, X Tian, W Yang… - Biomaterials …, 2015 - pubs.rsc.org
A7R peptide (ATWLPPR), a ligand of the NRP-1 receptor, regulates the intracellular signal
transduction related to tumor vascularization and tumor growth. Here, we designed A7R-
cysteine peptide (A7RC) surface modified paclitaxel liposomes (A7RC-LIPs) to achieve


For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to >99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.

Eva He
eva@pepmic.com
Pepmic Co., Ltd
www.pepmic.com


没有评论:

发表评论